Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit
05/24/2023 - 04:05 PM
REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker in a fireside chat at the TD Cowen 4th Annual Oncology Innovation Summit.
Details of the company’s participation are as follows:
TD Cowen 4 th Annual Oncology Innovation Summit Conference Dates: May 30-31, 2023 Fireside Chat Time/Date: 12:30 p.m. Eastern on Wednesday, May 31, 2023 Location: Virtual conference; webcast available To access the live webcast of the fireside chat, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations . Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI ) and RMC-6291(KRASG12C ) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRASG12D ) and RMC-0708 (KRASQ61H ), both of which are currently in IND-enabling development, RMC-8839 (KRASG13C ), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
RVMD Rankings
#2552 Ranked by Stock Gains
RVMD Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Redwood City
About RVMD
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.